A Pilot Study of Gleevec (Imatinib Mesylate) in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma
- Participants will take the study drug orally each day of each eight week treatment
- During all treatment cycles, participants will have a physical exam and will be asked
questions about their general health and specific questions about any problems they
might be having and any medications they may be taking.
- If the participant has skin lesion, photographs will be taken of the skin lesion to
assess the response of the tumor to study treatment. CT scans will be used to follow
the participants response to treatment.
- Blood tests, including chemistry, hematology, and other tests to measure any additional
effect of the study drug and disease status will also be performed.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the overall response rate of imatinib in patients with T NHL
Eric Jacobsen, MD
Dana-Farber Cancer Institute
United States: Institutional Review Board
|Dana-Farber Cancer Institute||Boston, Massachusetts 02115|